News
Iceland-based start-up expands women’s health portfolio with new acquisition
The acquisition is hoped to create new opportunities for innovation in digital therapeutics
The Reykjavik-based start-up Sidekick Health has acquired the digital health company PINK! in a bid to expand its women’s health portfolio.
This acquisition brings with it PINK! Coach, a digital application for breast cancer that aims to improve health-related quality of life and health literacy and address the psychological, psychosomatic and physical effects of breast cancer.
The move is hoped to advance Sidekick Health’s portfolio and “strengthen” its position in the digital therapeutics market.
Dr Tryggvi Thorgeirsson, co-founder and CEO of Sidekick Health, said: “The acquisition of PINK! aligns perfectly with our mission to transform healthcare globally through digital innovation.
“By integrating PINK!’s cutting-edge breast cancer prescription digital therapeutic into our portfolio, we are ready to offer an even more comprehensive portfolio of digital therapeutics to patients, including further expansion opportunities within women’s health and oncology.
“We are particularly excited to work with professor Dr Pia Wülfing and her impressive team, whose dedication and expertise in breast cancer support and women’s health have been truly inspirational. Pia’s leadership at PINK! has created a strong foundation that we are eager to build upon.”
Professor Dr Pia Wülfing, founder and CEO of PINK!, said: “Joining forces with Sidekick Health represents an exciting new chapter for PINK!.
“Together, we can leverage our combined expertise to make a profound impact on the lives of patients with breast cancer in Europe, North America, and beyond.”
She added: “This step will enable us to expand the reach of our digital health solutions, including with Sidekick’s partners, and continue to offer patients innovative solutions, providing better support and care for people living with cancer.”
The expertise of the two companies is expected to create new opportunities for innovation in digital therapeutics and expand the range and clinical impact of conditions addressed by Sidekick.
To receive the Femtech World newsletter, sign up here.
Fertility
‘Rejuvenated’ eggs raise hopes for improved IVF outcomes
Scientists say they have ‘rejuvenated’ human eggs, in work that could improve IVF success rates for older women.
The team reports that an age-related defect causing genetic errors in embryos may be reversed by supplementing eggs with a key protein.
In eggs donated by fertility patients, microinjection of the protein cut the share showing the defect from 53 per cent to 29 per cent.
The findings were presented at the British Fertility Conference in Edinburgh by researchers from the Max Planck Institute for Multidisciplinary Sciences in Göttingen.
The technique is being commercialised by Ovo Labs, co-founded by professor Melina Schuh, who led the research.
The approach targets problems in meiosis, the process where eggs halve their genetic material before fertilisation.
In older eggs, chromosome pairs can loosen and separate too soon, leading to embryos with too many or too few chromosomes, known as aneuploidy.
The researchers found levels of a protein called Shugoshin 1, which helps hold chromosome pairs together, decline with age. Microinjections appeared to restore this “molecular glue” and reduce errors.
Professor Schuh said: “Overall we can nearly halve the number of eggs with [abnormal] chromosomes. That’s a very prominent improvement.
“Most women in their early 40s do have eggs, but nearly all of the eggs have incorrect chromosome numbers. This was the motivation for wanting to address this problem.
“What is really beautiful is that we identified a single protein that, with age, goes down, returned it to young levels and it has a big effect.
We are just restoring the younger situation again with this approach.
Declining egg quality is a major reason IVF success rates fall steeply with age.
UK figures show an average birth rate of 35 per cent per embryo transferred for patients under 35, dropping to 5 per cent for women aged 43 to 44.
Dr Agata Zielinska, co-founder and co-chief executive of Ovo Labs, said: “Currently, when it comes to female factor infertility, the only solution that’s available to most patients is trying IVF multiple times so that, cumulatively, your likelihood of success increases.
“What we envision is that many more women would be able to conceive within a single IVF cycle.”
The approach would not extend fertility beyond menopause.
The team is in talks with regulators about a clinical trial.
Dr Güneş Taylor, of the University of Edinburgh, who was not involved, said: “This is really important work because we need approaches that work for older eggs because that’s the point at which most women appear.
“If there’s a one-shot injection that substantially increases the number of eggs with properly organised chromosomes, that gives you a better starting point.”
Insight
Number and timing of children linked to biological ageing, study finds
News
NHS doctor urges women to complete three health checks every month
-
Features4 weeks agoCannabis compounds kill ovarian cancer without harming healthy cells, research finds
-
Insight4 weeks agoMeta removes dozens of abortion advice and queer advocacy accounts
-
Insight4 days ago2025: The year IVF innovation went from lab to life
-
News3 weeks agoCan biotech help close the fertility gap? Inside the race to improve egg quality
-
Features4 weeks agoUniversity of Leeds IVF spinout raises £3.5m
-
Insight3 weeks agoAI-driven digital tool delivers sustained blood pressure reductions, study finds
-
Insight4 weeks agoMenopausal hormone therapy may not increase breast cancer risk in women with BRCA mutations
-
News3 weeks agoAHA invests in AI aimed at cardiology’s gender bias problem








1 Comment